Cargando…

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM) is increasing and there is an urgent need for new treatment strategy to prevent progression of hepatic steatosis and fibrosis. We have performed a systematic review and meta-analysis of rando...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yuan, Xu, Jiao, Zhang, Dong, Mu, Xingyu, Shi, Yi, Chen, Shangtao, Wu, Zengxiang, Li, Shuangqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696030/ https://www.ncbi.nlm.nih.gov/pubmed/34956080 http://dx.doi.org/10.3389/fendo.2021.769069

Ejemplares similares

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
por: Zeng, Qingyue, et al.
Publicado: (2023)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

A Case Report of Leukocytosis During Modified Electroconvulsive Therapy of Paranoid Personality Disorder
por: Mu, Xingyu, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
por: Meng, Zhuqing, et al.
Publicado: (2023)

Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
por: Min, Qiuxia, et al.
Publicado: (2022)

Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration
por: Jansen, Kirsten M., et al.
Publicado: (2023)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
por: Hu, Weiting, et al.
Publicado: (2022)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
por: Nevola, Riccardo, et al.
Publicado: (2023)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
por: Dai, Yuzhao, et al.
Publicado: (2021)

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Wei, Qiong, et al.
Publicado: (2021)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
por: Padda, Jaskamal, et al.
Publicado: (2021)

Association between dietary glycemic index and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
por: Salavatizadeh, Marieh, et al.
Publicado: (2023)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
por: He, Weiwei, et al.
Publicado: (2017)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease
por: Wu, Weiti, et al.
Publicado: (2021)

Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease
por: Hendrikx, Tim, et al.
Publicado: (2020)

Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease
por: Maruszczak, Katharina, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis
por: Tang, Qizhi, et al.
Publicado: (2022)

Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis
por: Ren, Mengting, et al.
Publicado: (2022)

Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis
por: Yuan, Xia, et al.
Publicado: (2023)

Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
por: Mandal, Amrendra, et al.
Publicado: (2018)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tb80easudd8filndrshi28bm08